GQG Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-620
Closed -$666K 90
2025
Q4
$666K Sell
620
-182
-23% -$174K ﹤0.01% 73
2025
Q3
$612K Sell
802
-271,792
-100% -$202M ﹤0.01% 81
2025
Q2
$213M Sell
272,594
-1,556,859
-85% -$1.21B 0.3% 49
2025
Q1
$1.51B Sell
1,829,453
-2,705,511
-60% -$2.25B 2.41% 14
2024
Q4
$3.5B Sell
4,534,964
-275,876
-6% -$228M 5.2% 3
2024
Q3
$4.26B Buy
4,810,840
+803,141
+20% +$722M 6.68% 3
2024
Q2
$3.63B Buy
4,007,699
+158,813
+4% +$127M 5.5% 5
2024
Q1
$2.99B Buy
3,848,886
+648,094
+20% +$461M 4.82% 5
2023
Q4
$1.87B Sell
3,200,792
-67,235
-2% -$39.2M 3.95% 7
2023
Q3
$1.76B Buy
3,268,027
+118,821
+4% +$61.2M 4.06% 7
2023
Q2
$1.48B Buy
3,149,206
+172,407
+6% +$72.3M 3.4% 13
2023
Q1
$1.02B Buy
2,976,799
+1,329,081
+81% +$448M 2.68% 16
2022
Q4
$603M Buy
1,647,718
+53,270
+3% +$18.9M 1.63% 21
2022
Q3
$515M Sell
1,594,448
-37,001
-2% -$11.7M 1.49% 23
2022
Q2
$529M Sell
1,631,449
-63,772
-4% -$19.1M 1.3% 25
2022
Q1
$485M Buy
1,695,221
+29,522
+2% +$7.6M 1.13% 27
2021
Q4
$460M Buy
1,665,699
+33,940
+2% +$8.6M 1.14% 31
2021
Q3
$377M Sell
1,631,759
-72,978
-4% -$18M 1.03% 31
2021
Q2
$391M Sell
1,704,737
-299,105
-15% -$60.1M 1.15% 30
2021
Q1
$374M Sell
2,003,842
-60,037
-3% -$11.7M 1.37% 27
2020
Q4
$348M Buy
2,063,879
+1,476,146
+251% +$220M 1.19% 29
2020
Q3
$87M Buy
+587,733
New +$91M 0.3% 50

Other funds holding LLY

GQG Partners's LLY Position: Q1 2026 in Review

GQG Partners sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 620 shares — an estimated $666K sold.

GQG Partners first reported a position in LLY in Q3 2020 and held it in 22 quarters. The position peaked at $4.26B in Q3 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • GQG Partners reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • GQG Partners sold 620 Eli Lilly shares in Q1 2026, an estimated $666K.
  • GQG Partners first reported a position in Eli Lilly in Q3 2020 and held it in 22 quarters.
  • GQG Partners's Eli Lilly position peaked at $4.26B in Q3 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on GQG Partners's 13F filing for Q1 2026, filed 12 May 2026.